MedTrace Logo

Pilot Study of the Human Metagenome in Metabolic Diseases

NCT06363253 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2025-05-15

No results posted yet for this study

Summary

This is a cohort study to understand the role of the human metagenome, and associated metabolites, in health and in various diseased states, in particular obesity as well as sarcopenia.

Recruited participants will have their fecal, salivary, urine, serum, and in certain instances, mucosal samples taken, for metagenomic sequencing and metabolite testing.

We hope to uncover various differences and signatures in the metagenome and metabolome in various diseased states, with potential future therapeutic applications in personalised medicine.

Conditions

Interventions

OTHER

No specific intervention

Patient will undergo their routine clinical treatment for their related clinical condition (eg. anti-obesity or bariatric intervention for obese group; muscle strengthening interventions or necessary treatment for their concomitant medical condition for the sarcopenia group). Follow-up testing will include repeat assessment of the subjects metagenome and metabolome over time, and after intervention Control subjects will have no interventions performed as well.

Sponsors & Collaborators

  • Singapore General Hospital

    collaborator OTHER

  • Lee Kong Chian School of Medicine, Nanyang Technological University

    collaborator UNKNOWN

  • Duke-NUS Graduate Medical School

    collaborator OTHER

  • Sengkang General Hospital

    lead OTHER

Eligibility

Min Age
21 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-14
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06363253 on ClinicalTrials.gov